Reaction

Haemorrhage Subcutaneous reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,515 reports · 77 co-occurring drugs

As of the last recalculation, Haemorrhage Subcutaneous appears in 3,515 FAERS reports alongside 77 co-occurring drug terms. The strongest observed disproportionality signal is FONDAPARINUX SODIUM (PRR 25.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Fondaparinux Sodium	34	25.1	25.2
Pitavastatin Calcium	27	15.7	15.8
Miconazole Nitrate	20	13.6	13.7
Alteplase	32	12.7	12.8
Febuxostat Tablets 40 Mg	21	12.3	12.3
Febuxostat Tablets 80 Mg	21	12.3	12.3
Emicizumab	25	12.1	12.1
Ibrutinib	119	9.0	9.0
Prasugrel Hydrochloride	15	8.8	8.8
Heparin Sodium	20	8.7	8.7
Febuxostat	23	8.2	8.2
Warfarin Sodium	62	8.0	8.0
Warfarin	159	7.7	7.7
Magnesium Oxide	48	6.9	6.9
Rivaroxaban	228	6.9	6.9
Dalteparin Sodium	12	6.7	6.7
Tranexamic Acid	10	6.7	6.7
Dabigatran Etexilate Mesylate	78	6.5	6.5
Dabigatran Etexilate	78	6.1	6.1
Clopidogrel Bisulfate	98	5.8	5.8
Raloxifene Hydrochloride	14	5.7	5.7
Romosozumab-Aqqg	13	5.7	5.7
Rabeprazole	20	5.4	5.4
Anti-Thymocyte Globulin (Rabbit)	7	5.1	5.2
Niraparib	18	4.8	4.8
Clopidogrel	154	4.8	4.8
Rifampicin	8	4.7	4.7
Suvorexant	10	4.6	4.6
Avapritinib	9	4.4	4.4
Sodium Chloride Tablet	53	4.3	4.3
Sodium Chloride Tablets	53	4.3	4.3
Ticagrelor	23	4.3	4.3
Isosorbide Dinitrate	14	4.3	4.3
Clarithromycin	24	4.2	4.2
Dexamethasone Sodium Phosphate	7	4.1	4.1
Dronedarone	7	4.1	4.1
Sodium Chloride	53	4.0	4.0
Isosorbide Mononitrate	14	4.0	4.0
Azacitidine	20	4.0	4.0
Goserelin	9	4.0	4.0
Gefitinib	6	3.9	3.9
Cytarabine	39	3.9	3.9
Misoprostol	6	3.7	3.7
Hydroxyurea	13	3.7	3.7
Abiraterone Acetate	25	3.6	3.6
Pravastatin Sodium	12	3.6	3.6
Micafungin Sodium	5	3.5	3.5
Acalabrutinib	7	3.4	3.4
Granisetron Hydrochloride	6	3.4	3.4
Linezolid	17	3.4	3.4
Voriconazole	17	3.3	3.3
Tolvaptan	8	3.3	3.3
Sunitinib Malate	21	3.2	3.2
Romiplostim	8	3.2	3.2
Sorafenib	11	3.1	3.1
Entecavir	6	3.0	3.0
Levocetirizine Dihydrochloride	12	3.0	3.0
Iohexol	4	2.9	2.9
Apixaban	32	2.8	2.8
Eltrombopag Olamine	11	2.8	2.8
Regorafenib	5	2.6	2.6
Pazopanib Hydrochloride	11	2.4	2.4
Riociguat	13	2.4	2.4
Azacitidine For	7	2.3	2.3
Deferasirox	10	2.2	2.2
Axitinib	7	2.1	2.1
Bosutinib	3	2.0	2.0
Daptomycin	3	1.9	1.9
Drospirenone And Ethinyl Estradiol	13	1.7	1.7
Onabotulinumtoxina	21	1.6	1.6
Methoxy Polyethylene Glycol-Epoetin Beta	3	1.6	1.6
Fremanezumab-Vfrm	3	1.5	1.5
Apalutamide	3	1.5	1.5
Sarilumab	6	1.3	1.3
Enzalutamide	13	1.3	1.3
Osimertinib	7	1.3	1.3
Alirocumab	5	1.2	1.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.